HCA reported fourth-quarter adjusted earnings of $8.01 per share, a 28.8% increase year over year, comfortably surpassing consensus estimates. Revenue rose 6.7% to $19.51 billion, driven by a 2.5% increase in equivalent admissions and a 2.9% rise in revenue per equivalent admission. Adjusted EBITDA climbed 10.8% to $4.11 billion, and margins expanded to 21.1% from 20.3% a year earlier, highlighting operational leverage from higher patient volumes and improved pricing trends.

Over the past year, HCA has deployed $10 billion to repurchase shares, reducing its outstanding share count by double-digit percentages and enhancing free cash flow yield to approximately 6%. Operating margins have steadily widened as the company leverages scale in supply chain management and cost controls. These buybacks, combined with margin gains, have underpinned a 40% total return for shareholders, although further margin benefits may be increasingly difficult to sustain.

For fiscal 2026, HCA projects adjusted earnings per share in the range of $29.10 to $31.50 and revenue between $76.5 billion and $80.0 billion, both above Wall Street forecasts. However, at roughly 16 times forward earnings, the stock’s valuation appears full, with limited upside in multiple expansion. Potential headwinds include proposed changes to Medicaid reimbursement and Affordable Care Act subsidies, which could pressure future margins if policy reforms reduce patient coverage or payment rates.